inTEST (INTT) CFO receives new stock and option awards in Form 4

Rhea-AI Filing Summary

inTEST Corp CFO Duncan Gilmour reported equity compensation awards, not open-market trading. He received an employee stock option for 9,736 shares of common stock at an exercise price of $14.47 per share, expiring in 2036, which will vest in four equal annual installments starting March 16, 2027.

He was also granted 5,760 time-based restricted shares that vest in four equal annual installments beginning on March 16, 2027, plus 5,760 performance-based restricted shares that may vest in March 2029 if specified performance goals are met, with a maximum of 8,640 shares eligible to vest at peak performance.

Following these awards, Gilmour holds 67,954 shares of common stock directly and 200 shares indirectly through his spouse, along with multiple previously granted stock options with exercise prices between $7.74 and $16.80 expiring from 2031 through 2035.

Insights

Equity compensation analyst

Routine equity awards increase the CFO’s long-term stock and option exposure.

The filing shows CFO Duncan Gilmour receiving stock options and restricted shares as part of inTEST’s 2023 Stock Incentive Plan. These awards vest over several years and are granted at no cash cost to him on the grant date.

The package combines time-based restricted stock, performance-based restricted stock, and a stock option at an exercise price of $14.47 per share, expiring in 2036. Vesting schedules stretching to 2029 are designed to align compensation with both service and future performance outcomes.

The transactions do not involve any share sales or exercises, and he retains substantial existing option positions with exercise prices between $7.74 and $16.80, expiring from 2031 through 2035. Overall, this appears to be routine, plan-based compensation rather than a directional trading signal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gilmour Duncan

(Last) (First) (Middle)

C/O INTEST CORP

804 EAST GATE DR, SUITE 200

(Street)

MT. LAUREL NEW JERSEY 08054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTEST CORP [ INTT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO, Treasurer & Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		A		5,760(1)	A	$0	62,194	D
Common Stock	03/16/2026		A		5,760(2)	A	$0	67,954	D
Common stock								200	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$14.47	03/16/2026		A		9,736		(3)	03/15/2036	Common Stock	9,736	$0	9,736	D
Employee Stock Option (right to buy)	$7.74							(4)	03/16/2035	Common Stock	1,992		1,992	D
Employee Stock Option (right to buy)	$7.74							(4)	03/16/2035	Common Stock	18,077		18,077	D
Employee Stock Option (right to buy)	$11.33							(5)	03/05/2034	Common Stock	12,724		12,724	D
Employee Stock Option (right to buy)	$16.06							(6)	03/07/2033	Common Stock	8,044		8,044	D
Employee Stock Option (right to buy)	$9.76							(7)	03/08/2032	Common Stock	12,848		12,848	D
Employee Stock Option (right to buy)	$16.8							(7)	06/13/2031	Common Stock	8,104		8,104	D

Explanation of Responses:

1. These restricted shares were granted pursuant to the InTest Corporation 2023 Stock Incentive Plan (the "Plan") in a transaction exempt under Rule 16b-3 and will vest in four equal annual installments commencing on March 16, 2027.

2. These performance-based restricted shares were granted pursuant to the Plan in a transaction exempt under Rule 16b-3 and will vest in March 2029 dependent upon certain performance criteria. The amount shown reflects the number of shares that will vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 8,640.

3. This option was granted pursuant to the Plan in a transaction exempt under Rule 16b-3 and will vest in four equal annual installments commencing on March 16, 2027.

4. This option vests in four equal annual installments commencing on March 17, 2026.

5. This option vests in four equal annual installments commencing on March 6, 2025.

6. This option vests in four equal annual installments commencing on March 8, 2024.

7. This option is fully vested as of the date of this report.

	/s/ Duncan Gilmour	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did inTEST (INTT) CFO Duncan Gilmour receive?

Gilmour received a stock option for 9,736 shares at an exercise price of $14.47 plus two restricted stock grants of 5,760 shares each, one time-based and one performance-based. All awards were issued under inTEST’s 2023 Stock Incentive Plan.

How do the new restricted stock awards for inTEST CFO vest?

The 5,760 time-based restricted shares vest in four equal annual installments starting on March 16, 2027. The 5,760 performance-based restricted shares may vest in March 2029 depending on performance, with up to 8,640 shares vesting at maximum performance levels.

What are the terms of Duncan Gilmour’s new inTEST stock option grant?

The new employee stock option covers 9,736 inTEST common shares at an exercise price of $14.47 per share and expires in 2036. It vests in four equal annual installments beginning on March 16, 2027, subject to continued service under the company’s incentive plan.

How many inTEST shares does the CFO hold after these Form 4 transactions?

After the reported awards, Gilmour holds 67,954 inTEST common shares directly and 200 shares indirectly through his spouse. These positions are in addition to multiple outstanding employee stock options with various exercise prices and expirations disclosed in the filing’s derivative holdings table.

Were there any inTEST (INTT) insider share sales in this Form 4?

No share sales were reported. All Form 4 entries for March 16, 2026 reflect grant or award acquisitions and existing holdings. The filing records new option and restricted stock awards to the CFO, with no open-market purchases, exercises, or dispositions disclosed.

What other stock options does the inTEST CFO have outstanding?

Beyond the new grant, Gilmour holds several existing employee stock options on inTEST common stock with exercise prices between $7.74 and $16.80, expiring from 2031 through 2035. Vesting schedules for these earlier grants are described in the accompanying footnotes.